1-(3-碘-2-吡啶基)哌嗪 | 85386-98-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-碘-2-吡啶基)哌嗪
• 中文别名: 1-(3-碘吡啶)哌嗪；1-(3-碘吡啶-2-基)哌嗪
• 英文名称: 1-(3-iodopyridin-2-yl)piperazine
• CAS: 85386-98-7
• 化学式: C₉H₁₂IN₃
• mdl: MFCD04039872
• 分子量: 289.119
• InChiKey: YEMFQTAXPFSLAE-UHFFFAOYSA-N

物化性质

• 熔点：
  63.1-67.8°C
• 稳定性/保质期：
  按规定使用和贮存的不会分解，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 储存条件：
  存于密闭、阴凉、干燥处

反应信息

• 作为反应物：
  描述：

  吲哚美辛 、 1-(3-碘-2-吡啶基)哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Synthesis and evaluation of [¹²³I]-indomethacin derivatives as COX-2 targeted imaging agents

  摘要：

  合成了一系列含碘的吲哚美辛衍生物，并对其作为COX-2选择性抑制剂进行了评估。两种候选化合物N-(对碘苄基)-2-(1-(对氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-基)乙酰胺(3)和1-(对碘苄基)-5-甲氧基-2-甲基-3-吲哚乙酸(9)具有适用于潜在体内成像的最优特性。通过含碘化合物与六丁基锡和四(三苯基膦)钯(0)在二恶烷中回流反应，合成了产率为70-85%的放射性碘化锡的芳基锡烷前体。通过在pH 3.5的酸性条件下，含载体的Na[123I]在氯胺T存在下与EtOAc/H2O二元体系反应进行放射性碘化锡反应，直接通过有机相分离分离出标记产物。放射性碘标记产物[123I]3和[123I]9的衰减校正放射化学产率为86-87%，放射化学纯度为98-99%。

  DOI：

  10.1002/jlcr.1615
• 作为产物：
  描述：

  哌嗪 、 2-氯-3-碘吡啶 以 正丁醇 为溶剂， 反应 18.0h， 生成 1-(3-碘-2-吡啶基)哌嗪
  参考文献：
  名称：

  Pyridinylpiperazines, a new class of selective .alpha.2-adrenoceptor antagonists

  摘要：

  A series of 1-(2-pyridinyl)piperazine derivatives was synthesized and evaluated for adrenergic activity. In vitro activity was assessed through the antagonism of clonidine's effect in the rat, isolated, field-stimulated vas deferens and by the displacement of [3H]clonidine from membrane binding sites of calf cerebral cortex. Antagonism of clonidine-induced mydriasis in the rat was used as an in vivo assay. Several members of the series proved to be potent, selective alpha 2-adrenoceptor antagonists. 1-(3-Fluoro-2-pyridinyl)piperazine was more potent than either yohimbine or rauwolscine in displacement of [3H]clonidine and had a higher affinity for this binding site (alpha 2) than for the [3H]prazosin site (alpha 1). In vivo, the 3-F derivative was more potent than the reference standards in reversing clonidine-induced mydriasis. None of the members of this series was more selective or potent than rauwolscine in antagonizing clonidine in the rat vas deferens.

  DOI：

  10.1021/jm00366a007

文献信息

• DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
  申请人：Wang Tao

  公开号：US20070249579A1

  公开（公告）日：2007-10-25

  This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

  本公开提供具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该公开涉及具有独特抗病毒活性的二酮哌嗪和哌啶衍生物。更具体地说，本公开涉及用于治疗艾滋病毒和艾滋病的化合物。
• Indol-3-y-carbonyl-piperidin and piperazin-derivatives
  申请人：Bissantz Caterina

  公开号：US20070027163A1

  公开（公告）日：2007-02-01

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哒-3-基甲酰哌啶和哌嗪衍生物，其由以下式I表示：其中残基R1至R3如本文所定义。该发明还涉及含有这种化合物的药物组合物，以及制备这些化合物和组合物的方法。该发明还涉及治疗痛经、高血压、慢性心力衰竭、抗利尿素过度分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20120040990A1

  公开（公告）日：2012-02-16

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及一种作为V1a受体拮抗剂的吲哚-3-基甲酰基哌啶和哌嗪衍生物，其由式I表示：其中残基R1至R3如本文所定义。本发明还涉及含有此类化合物的制药组合物，以及制备该化合物和组合物的方法。本发明还涉及治疗痛经、高血压、慢性心力衰竭、不适当分泌加压素、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• Indol-3-yl-carbonyl-piperidin and piperazin derivatives
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2392571A2

  公开（公告）日：2011-12-07

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R1 to R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in medicaments against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders, and methods of preparation thereof.

  本发明涉及可作为 V1a 受体拮抗剂的吲哚-3-羰基哌啶和哌嗪衍生物，它们由式 I 表示： 其中残基 R1 至 R3 如本文所定义。本发明进一步涉及含有此类化合物的药物组合物，它们在治疗痛经、高血压、慢性心力衰竭、血管加压素分泌不当、肝硬化、肾病综合征、强迫症、焦虑症和抑郁症的药物中的用途及其制备方法。
• Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure−Activity Relationships of 2-Piperazin-1-yl-1<i>H</i>-benzimidazoles
  作者：Vassil I. Ognyanov、Chenera Balan、Anthony W. Bannon、Yunxin Bo、Celia Dominguez、Christopher Fotsch、Vijay K. Gore、Lana Klionsky、Vu V. Ma、Yi-Xin Qian、Rami Tamir、Xianghong Wang、Ning Xi、Shimin Xu、Dawn Zhu、Narender R. Gavva、James J. S. Treanor、Mark H. Norman

  DOI：10.1021/jm060065y

  日期：2006.6.1

  The vanilloid receptor-1 ( VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2-ylpiperazin-1-yl)-1H-benzo-[ d] imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant ( CFA).